Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (hereinafter “SEBI Listing Regulations”) read with Para A-Part A of Schedule III of the SEBI Listing Regulations, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force Ind-Swift Laboratories has informed that it has approved the incorporation of a wholly owned subsidiary in Dubai, United Arab Emirates (UAE) in the name and style of Ind-Swift (Dubai) or such other name as may be approved by the concerned authorities of the UAE. The Company shall further intimate on receipt of Certificate of Incorporation as and when the same is received by the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: